Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

NCT02915744 is registered in ClinicalTrials.gov with Nektar Therapeutics as lead sponsor.

NCT NCT02915744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02915744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
Lead sponsor
Nektar Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2016
Completion date
July 31, 2020
Enrollment
178 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, metastasis